LEVOTHYROXINE MANUFACTURERS HAVE THREE YEARS TO OBTAIN NDA APPROVAL UNDER FDA POLICY; AGENCY CITES POTENCY AND STABILITY PROBLEMS WITH THYROID PRODUCTS
FDA is giving manufacturers of levothyroxine sodium three years to obtain NDA approval for their products under a new drug policy announced Aug. 14.